BridgeBio Oncology Therapeutics Inc. (BBOT) vs TriSalus Life Sciences, Inc. (TLSI)
A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and TriSalus Life Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBOT
BridgeBio Oncology Therapeutics Inc.
$3.52HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
TLSI
TriSalus Life Sciences, Inc.
$4.32HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — BBOT vs TLSI
growth of $100 · dividends reinvested · last 3yBBOT -64.7% (-29.3%/yr)TLSI -54.9% (-23.3%/yr)TLSI compounded faster over this window
BBOT TLSI
BBOT vs TLSI: by the numbers
- •BBOT is the larger company ($282M vs $266M market cap).
- •Both run net losses; BBOT's is the smaller (0.00% vs -62.59% net margin).
Metrics side by side
Valuation
| Metric | BBOT | TLSI |
|---|---|---|
| P/S ratio | N/A | 5.90 |
| P/B ratio | 0.87 | 40.61 |
Profitability
| Metric | BBOT | TLSI |
|---|---|---|
| Gross margin | 0.00% | 85.79% |
| Operating margin | 0.00% | -59.68% |
| Net margin | 0.00% | -62.59% |
| ROE | -56.36% | -430.72% |
| ROIC | -61.10% | -59.50% |
Growth (annualized)
| Metric | BBOT | TLSI |
|---|---|---|
| Total return CAGR (5Y) | N/A | -15.05% |
Go deeper
Dig into the metrics
BridgeBio Oncology Therapeutics ROETriSalus Life Sciences ROEBridgeBio Oncology Therapeutics operating marginTriSalus Life Sciences operating marginBridgeBio Oncology Therapeutics revenue growthTriSalus Life Sciences revenue growthBridgeBio Oncology Therapeutics free cash flowTriSalus Life Sciences free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.